The International CardiOncology Society
An Update for 2014
Daniel J Lenihan, MD
Professor, Division of Cardiovascular Medicine
Director, Clinical Research
Vanderbilt University
The International CardiOncology Society
An Update
•
•
•
•
•
Exactly what does this society mean?
How do we do things?
What are our goals?
How do we achieve them?
Is there really a future for this?
ICOS is:
• A collection of interested providers
focused on improving cardiac health in
cancer patients
• A mix of academic, practice,
governmental, regulatory, and industry
professionals
• Committed to our patients wherever they
are
The International CardiOncology Society
An Update
•
•
•
•
•
Exactly what does this society mean?
How do we do things?
What are our goals?
How do we achieve them?
Is there really a future for this?
We do things in many ways:
•
•
•
•
•
•
Day to day improvement in our practices
Monthly webinars available to all
Periodic presentations at major meetings
Annual ICOS congresses
Development of current “Best Practice”
Data review for ongoing early phase and late phase
clinical trials
• Ongoing participation in major professional society
efforts
• Ongoing individual and multicenter research
• Consistent involvement with regulatory agencies in many
countries
The International CardiOncology Society
An Update
•
•
•
•
•
Exactly what does this society mean?
How do we do things?
What are our goals?
How do we achieve them?
Is there really a future for this?
ICOS goals
• Research
– Engage large databases
– Cardiac safety endpoint
adjudication
– Hypothesis testing
research
• Advocacy
• Patients/families
• Providers
• Education
– Provider case review
– Patient directed
– Professional meetings
– Industry/regulatory webinars
– Trainee organization
• Be a Resource
• Up to Date information
• Identify Goals for the future
• Provide innovation
• Be an example of
collaboration
Number of PUBMED articles on Cardio-Oncology
400
350
300
250
200
150
100
50
0
1971
2014
www.oncoreview.pl
The International CardiOncology Society
An Update
•
•
•
•
•
Exactly what does this society mean?
How do we do things?
What are our goals?
How do we achieve them?
Is there really a future for this?
PREDICT Study:
A multicenter study in Patients undergoing
anthRacycline-based chemotherapy to assess the
Effectiveness of using biomarkers to Detect and
Identify Cardiotoxicity and describe Treatment
Daniel J Lenihan, MD
Professor, Division of Cardiovascular Medicine
Vanderbilt University
CCOP Annual Meeting 2010
Total
Accrual:
597
patients
In the case of
HER2+ breast
cancer, treatment
clearly benefitted
the disease but
came at a cost
Slamon D et al; NEJM
2011:365:1273-83
The effect of time for initiation of HF
therapy and the percent of patients who
improve
Responders (%)
100
80
64%
60
28%
40
7%
20
0%
0%
0%
0%
0
1-2
2-4
4-6
6-8
8-10
10-12
(n=75)
(n=35)
(n=20)
(n=12)
(n=8)
(n=7)
>12 months
(n=44)
D Cardinale, et al. JACC 2010, jan 26.
In regards to Ischemic insults, we have a
paradigm
Kloner et al, Circ 2001; p2981
Statin therapy prior to and during
chemotherapy was protective
JACC 2012, p 2384
Prevention of Cardiotoxicity is possible
Bosch, X et al, JACC 2013, p 2355
Are there things on the cancer therapy
horizon that could be concerning for
cardiomyopathy?
There is a balance between protein synthesis and
degradation
Monte S. Willis, M.D., Ph.D., and Cam Patterson, M.D., M.B.A.
NEJM 2013;368:455-64.
Dick,LR and Flemming,PE Drug
Discovery Today ;15 (5/6) March 2010
The International CardiOncology Society
An Update
•
•
•
•
•
Exactly what does this society mean?
How do we do things?
What are our goals?
How do we achieve them?
Is there really a future for this?
A Paradigm for Cardiology Oncology Cooperation
Kouri M et al. Circulation 2012
ICOS=
A public, private, patient, provider,
regulatory, governmental PARTNERSHIP
www.icosna.org